What Ciclovular Treats: Main Uses and Benefits

Ciclovular, a combined hormonal injection, is used in contexts focused on reproductive health and cycle-related symptoms. The primary therapeutic domain is the systemic prevention of pregnancy, an established contraceptive option relevant for easing the symptomatic burden associated with fertility management.

It is applied in family planning where patients seek long-term, non-daily support; the non-daily schedule is relevant when compliance with daily methods is a concern, and this contributes to consistent contraceptive protection. Ciclovular may assist with managing disruptive menstrual cycle abnormality symptoms. It is commonly used to help address groups of symptoms that may become intense, such as painful menstruation (dysmenorrhea), episodes of excessive menstrual bleeding (menorrhagia), and contributes to cycle regulation. The medicine is considered relevant for managing hormone-related skin symptoms like acne, offering a secondary benefit that may assist with managing the symptomatic burden.

---

Quick Fact: Relief for Painful Menstruation

Symptom Type	Condition Context	Patient Benefit
Painful periods (Dysmenorrhea)	Recurrent episodes that interfere with daily functioning	Assists with maintaining functional stability during symptomatic periods

Regulatory References

1. NIH MeSH Database entry for Algestone Acetophenide

Official Eligibility and Contraindications

Ciclovular, as a combined hormonal contraceptive, is intended for use in women of childbearing potential who do not have specific contraindications listed in the official labeling. Use is not indicated for post-menopausal women and is contraindicated before menarche.

Contraindication Category	Exclusion Status
Thromboembolic Risk	Absolute Contraindication for active or history of arterial or venous thromboembolic disorders (e.g., DVT, PE, stroke, MI), Migraine with aura, or known thrombogenic conditions.
Reproductive Status	Absolutely Contraindicated during known or suspected pregnancy. Not recommended during breastfeeding in the initial postpartum period.
Organ/Systemic Disease	Absolute Contraindication for severe hepatic impairment, liver tumors, severe uncontrolled hypertension, or sex-hormone-dependent malignancies.

Use requires close monitoring and caution in populations with specific risk factors, such as women smoking over the age of 35, or those with well-controlled hypertension or uncomplicated diabetes mellitus. The regulatory profile defines eligibility primarily by the mandatory exclusion of these high-risk clinical conditions, ensuring that only populations free of these severe vascular, hepatic, or oncogenic risks may use the medicine.

Interactions with other medicines and products

This section summarizes the officially documented information regarding the interactions of Ciclovular with other medicinal products and substances, as stated in regulatory labeling.

---

Interaction Scope and Management

Ciclovular is primarily involved in interactions related to the Cytochrome P450 3A4 (CYP3A4) enzyme and the P-glycoprotein (P-gp) transporter. Official regulatory documents structure the interaction profile based on the effect of co-administered medicines on Ciclovular's plasma concentrations.

Interacting Category	Regulatory Implication
Strong CYP3A4 Inducers	Contraindicated (Avoid use due to significant loss of efficacy).
Strong/Moderate CYP3A4 Inhibitors	Requires Dose Adjustment (Monitor and potentially reduce the dose of Ciclovular).
P-gp Modulators (Inhibitors/Inducers)	Use with Caution (Requires close clinical monitoring for altered absorption).
Sensitive CYP2D6 Substrates	Risk of Increased Toxicity (Ciclovular may inhibit the metabolism of these co-administered drugs).

---

Official Interaction Statements

Concomitant use with strong inducers of CYP3A4 is strictly contraindicated, as this combination can lead to a substantial and clinically significant decrease in Ciclovular exposure. Conversely, co-administration with strong or moderate CYP3A4 inhibitors may significantly increase Ciclovular concentrations, necessitating a specific downward dose modification. The label notes that inhibitors or inducers of the P-gp transporter may alter the drug's disposition. Furthermore, Ciclovular may inhibit the metabolism of certain co-administered medicinal products that are sensitive substrates of the CYP2D6 enzyme, increasing the risk of adverse effects from the co-administered drug.

How Ciclovular Works

Ciclovular functions via suppression of the Receptor Activator of NF-kappaB Ligand (RANKL) pathway, which mediates osteoclastogenesis. Ciclovular operates as an inhibitor by binding directly to circulating RANKL, thereby preventing its interaction with the Receptor Activator of NF-kappaB (RANK) on the osteoclast precursor surface.

This binding event modulates the subsequent intracellular signaling cascade necessary for osteoclast maturation and activity. This cellular modulation consequently influences the overall balance between bone formation by osteoblasts and bone resorption by osteoclasts in the skeletal system. The resulting physiological consequence of this targeted inhibition of osteoclast activity is the modulation of bone mineral density.

How to Use Ciclovular

Ciclovular is a Combined Injectable Contraceptive (CIC) administered via a precise, fixed-interval schedule. Its use is based on a structured, professional protocol rather than daily self-administration.

Administration Method and Dosing

Ciclovular is authorized for use as an intramuscular (IM) injection. The sterile solution is typically administered into a large muscle mass, such as the gluteal or deltoid region, to facilitate a depot effect and sustained release of the hormones.

Usage Component	Official Labeled Instruction
Route of Administration	Deep Intramuscular (IM) Injection
Standard Dosing Unit	One fixed-dose unit containing 150 mg Algestone Acetophenide and 10 mg Estradiol Enantate
Frequency Pattern	Once monthly, at a fixed interval

Schedule and Protocol

The most common labeled schedule requires the injection to be administered once every 28 to 30 days for continuous contraceptive coverage. This strict, cyclic timing is essential to maintain hormone levels necessary for the intended effect.

The initial injection is often scheduled to occur within the first five days of the menstrual cycle. Subsequent injections must adhere closely to the designated monthly interval. The administration requires a healthcare setting and must be performed by a qualified professional due to the specialized nature of the parenteral route and the need for precision. The formulation is a pre-mixed oily solution and is not intended for user preparation or dilution.

Ciclovular: Recent Clinical Evidence

---

Ciclovular (a combination of Algestone Acetophenide and Estradiol Enanthate) is a monthly intramuscular injection used for contraception. Clinical evidence for this formulation, primarily emerging from large-scale studies in Latin America and other regions, supports its efficacy and acceptability as a periodic hormonal contraceptive.

Efficacy and Safety Profile

Comparative, double-blind, and long-term open-label trials have consistently demonstrated the high contraceptive effectiveness of the monthly injectable. The primary mechanism of action involves the inhibition of ovulation, supported by alterations to the cervical mucus and endometrium.

• Contraceptive Efficacy: Studies involving thousands of cycles of use have reported low pregnancy rates, comparable to established combined oral contraceptives when used correctly. The monthly administration schedule is often cited by users as a factor contributing to high compliance and continuation rates.

• Bleeding Pattern: The formulation generally provides good cycle control. Common side effects are typical of hormonal contraceptives, including changes in menstrual bleeding patterns (such as intermenstrual spotting or changes in flow), headaches, and breast tenderness. These effects often decrease in frequency over the first several cycles of use.

• Long-Term Safety: Clinical monitoring over extended periods has evaluated systemic effects. As with all combined hormonal contraceptives, a key consideration is the risk of thromboembolic events. Evaluation of coagulation parameters in users has been a focus of some studies, with overall safety assessments aligning with the known profile of combined estrogen and progestin methods. The balance of efficacy and a generally manageable side-effect profile continues to support its role as an effective family planning option.

Common questions about Ciclovular (FAQ)

Q: What is the main difference between Ciclovular and other medicines used for the same purpose?

A: Ciclovular is classified as a Combined Injectable Contraceptive (CIC) that contains two types of hormones. Its essential difference from daily contraceptive methods is its method of use: it is administered as a single intramuscular injection by a healthcare professional once every 28 to 30 days. This schedule is designed to maintain consistent hormone levels for contraceptive action.

Q: Does official sources mention any mental or mood changes linked to Ciclovular?

A: Official regulatory documents for this class of medicine state that mood changes, mood swings, or depression are among the adverse reactions that have been reported during use. These effects are often listed under psychiatric disorders in the official product information summary.

Q: What official information is available about Ciclovular's effectiveness?

A: Official information describes Ciclovular's contraceptive effectiveness as comparable to established combined oral contraceptives. Clinical trials have reported low pregnancy rates that align with the required standards for this type of medication when used correctly according to the defined schedule.

Q: Why do some people stop taking Ciclovular?

A: Clinical studies tracking long-term use have found that common reasons for discontinuation are often related to changes in the menstrual cycle. Irregular bleeding or spotting between periods and the absence of periods (amenorrhea) are frequently cited reasons for stopping use, along with other general hormonal side effects.

Q: How quickly does Ciclovular usually start working?

A: Official prescribing information indicates that contraceptive coverage begins after the first injection if it is administered within the first five days of the menstrual cycle. Official labeling may recommend the use of additional non-hormonal protection during the initial days of use.

Q: Does Ciclovular have a generic version available?

A: The specific combination of the active ingredients, Algestone Acetophenide and Estradiol Enantate, is marketed under various brand names in different regions globally. The availability of a specific generic product name in a particular country can vary.

Q: Is Ciclovular the kind of drug you take for a long time or just short-term?

A: According to official product information, Ciclovular is intended for the long-term systemic prevention of pregnancy in women of childbearing potential who do not have contraindications. The official guidance advises ongoing monitoring for established safety risks associated with long-term use.

Q: What happens if I miss taking Ciclovular one day?

A: Official labeling contains a specific protocol for how to handle a delayed or missed monthly injection. Missing the scheduled date by more than a few days requires a specific course of action, which may include the use of an alternative contraceptive method to ensure continued protection.

Q: Can older adults typically use Ciclovular?

A: Ciclovular is a combined hormonal contraceptive and is indicated for women of childbearing potential. Official regulatory documents state that the medication is not indicated for use by post-menopausal women or those who are past the age of having their menstrual periods.

Q: Do children ever take Ciclovular?

A: Official regulatory documents state that the use of Ciclovular is contraindicated (not allowed) before the onset of the first menstrual period, a biological stage called menarche. Therefore, it is not administered to children.

Q: Can Ciclovular be cut in half or crushed?

A: Ciclovular is formulated as a sterile liquid solution that is administered via an intramuscular injection. Because it is a liquid for injection and not a solid tablet or capsule, it cannot be cut, chewed, or crushed.

Q: Are there different strengths of Ciclovular available?

A: The active ingredients in Ciclovular (Algestone Acetophenide and Estradiol Enantate) are sometimes formulated and marketed in different strengths (dosages) of the two hormone components. The availability of these different formulations depends on the specific product and regional regulatory approval.

Q: Can people who are pregnant or breastfeeding use Ciclovular?

A: Official labeling states that Ciclovular is absolutely contraindicated (not allowed) during known or suspected pregnancy. Furthermore, it is generally not recommended for use in the initial postpartum period while a person is breastfeeding.

Q: Is Ciclovular available over the counter?

A: According to regulatory classification, Ciclovular is a prescription-only medicine (POM). It is therefore not available for purchase over the counter (OTC) and requires a professional prescription and administration.

Q: Is it true that Ciclovular interacts with supplements like St. John's wort?

A: Official regulatory documents include a warning against using Ciclovular with medicines or supplements that are strong inducers of the CYP3A4 enzyme. St. John’s wort is often cited as a strong inducer of this enzyme, and concomitant use is generally contraindicated due to the potential for a significant decrease in Ciclovular’s efficacy.

Q: How long does the effect of one dose of Ciclovular last?

A: The administration schedule is set to ensure the medicine maintains its intended action for the full period between doses. The schedule focuses on maintaining the necessary hormonal concentration for the 28 to 30 day interval between injections, providing continuous contraceptive coverage.

Q: Are there any specific laboratory tests required before or during treatment with Ciclovular?

A: Official documents require ongoing monitoring of blood pressure during use. Depending on individual health factors, regulatory guidance may advise the evaluation of other parameters, such as blood clotting (coagulation) parameters and liver function.

Q: Does taking Ciclovular at night or in the morning make a difference?

A: Since Ciclovular is a long-acting injection with a sustained effect, the dosing schedule focuses on maintaining a strict monthly interval of 28 to 30 days between injections. The specific time of day the injection is administered by the professional is generally not considered a factor in maintaining its effectiveness.

Q: Is Ciclovular safe to use if I am scheduled for surgery?

A: Regulatory labeling requires that use of Ciclovular must be discontinued for at least four weeks prior to and for two weeks after any elective surgery that is associated with an increased risk of blood clots (thromboembolism).

Q: Are headaches a common side effect of Ciclovular?

A: Clinical trial data indicates that headaches are classified as a common adverse reaction associated with the use of this class of medication. These effects are usually reported by between 1% and 10% of users during studies.

Q: How do regulatory bodies classify the safety of Ciclovular for long-term use?

A: The safety profile for Ciclovular, particularly for long-term use, is actively managed by regulatory bodies through specific warnings and required monitoring. Key concerns involve the potential for serious adverse reactions, such as thromboembolic events, which necessitates ongoing clinical oversight.

Q: Is the research on Ciclovular mainly focused on adults?

A: Clinical research and evidence for Ciclovular are focused on its approved indication, which is contraception in women of childbearing potential. This group is defined as women who have started menstruating (post-menarche) and are not post-menopausal.

How to Store and Dispose of Ciclovular

Official regulatory documents define strict requirements for the storage, handling, and disposal of this medication to maintain its potency and ensure safety.

Storage Requirement	Official Guideline
Temperature	Store below 30 C (Controlled Room Temperature). Do not refrigerate or freeze.
Protection	Keep the product in the original container and outer packaging to protect it from light and moisture.
Handling	Store in a secure location, such as a locked cabinet, to prevent unauthorized access by children or pets.

Unused or expired Ciclovular must be disposed of properly according to federal, state, or local regulations. Disposal generally requires using authorized drug take-back programs or following non-retrievable disposal methods as directed in the drug's official labeling. Do not flush the medication down a toilet or pour it down a drain unless specifically instructed to do so.